Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene : Melanoma Research

Journal Logo

Short Communications: Clinical Research

Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene

Boileau, Mariea,b,c; Descarpentries, Clotildeb,d; Delzenne, Guillaumea,c; Trentesaux, Victorinea; Greliak, Annaa,b; Jamme, Philippea,b; Marchetti, Philippeb,c,e; Mortier, Laurenta,b

Author Information
Melanoma Research 33(3):p 247-251, June 2023. | DOI: 10.1097/CMR.0000000000000882

Abstract

Currently, in the absence of BRAFV600 mutation, the management of advanced melanomas is based on immunotherapies, but only half of the patients are responders. RAF1 (also named CRAF) fusions occur in 1–2.1% of wild-type melanomas. Preclinical data suggest that the presence of RAF fusion may be sensitive to MEK inhibitors. We report the case of a patient with an advanced melanoma harboring an EFCC1–RAF1 fusion who showed a clinical benefit from and a partial response to a MEK inhibitor.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid